-
If providers worry that The Joint Commission (TJC) will release their accreditation records to prosecutors, they may become reluctant to share sensitive information with the accrediting body, cautions Vickie Patterson, an associate director in the Atlanta office of Protiviti, a risk consulting firm.
-
Risk managers expect accreditation records to be confidential, and The Joint Commission (TJC) urges providers to fully disclose information about adverse events and deficiencies as part of the quality improvement process. But some risk managers are learning that those records are not as private as often thought.
-
-
Examining the three arms of the ACCORD trial; and FDA Actions: clopidogrel, dexlansoprazole, and tamsulosin.
-
-
Health care clinicians and organizations likely will find that the new health care reform bill's positive features outweigh its drawbacks, experts say.
-
Prabhakaran S, et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2010;67: (doi:10.1001/archneurol.2010.25).
-
This large retrospective study reports an overall poor prognosis for patients with GBM, but treatment was not "state-of-the-art."
-
This prospective case series reports on the efficacy and safety of levetiracetam in central nervous system gliomas.
-
The presence of conjugate eye deviation as measured by CT or MRI in acute stroke patients predicts visuo-spatial neglect. Prismatic therapy produces a cross-modality improvement in left-sided auditory extinction in patients with chronic right-sided stroke.